A 72-year-old man with COPD presents with his fourth exacerbation in the past 12 months. He is currently on triple therapy with tiotropium, salmeterol/fluticasone combination inhaler, and uses salbutamol as needed. He is an ex-smoker who stopped 5 years ago. Sputum cultures during previous exacerbations have grown Haemophilus influenzae on three occasions. His FEV1 is 38% predicted. He continues to have a productive cough with purulent sputum between exacerbations. What additional long-term treatment should be considered?
Q22
A 35-year-old woman who is 12 weeks pregnant presents with a 4-day history of cough productive of purulent sputum, fever, and left-sided chest pain. On examination, she is pyrexial at 38.2°C with a respiratory rate of 22/min and oxygen saturation of 94% on air. Chest examination reveals reduced breath sounds and dullness to percussion at the left lower zone. She has no past medical history and no known drug allergies. What is the most appropriate antibiotic choice?
Q23
A 44-year-old man attends the respiratory clinic for consideration of biologic therapy for his severe asthma. Despite maximal inhaled therapy (high-dose ICS/LABA plus LAMA) and maintenance oral prednisolone 10mg daily, he continues to have frequent exacerbations requiring hospital admission. Blood tests show: total IgE 850 IU/mL (normal <120), eosinophils 0.8 × 10⁹/L. Skin prick testing is positive to house dust mite and grass pollen. Which biologic agent would be the most appropriate first-line choice for this patient?
Q24
A 50-year-old woman is admitted with community-acquired pneumonia. She scores 2 on CURB-65 assessment. Blood cultures are taken and she is started on empirical antibiotic therapy. After 48 hours, she remains pyrexial with ongoing tachypnoea and hypoxia. Repeat chest radiograph shows progression of consolidation with a small pleural effusion. Blood cultures are negative. What is the most appropriate next step in her management?
Q25
According to BTS/SIGN guidelines for asthma management, what is the recommended starting dose of inhaled corticosteroid (beclometasone dipropionate equivalent) for an adult newly diagnosed with asthma requiring regular preventer therapy?
Q26
A 56-year-old woman undergoes a CT pulmonary angiogram for suspected pulmonary embolism following an episode of pleuritic chest pain and breathlessness. The scan confirms a segmental PE in the right lower lobe. She has no past medical history and takes no regular medications. Her observations are: heart rate 88/min, blood pressure 128/76 mmHg, respiratory rate 18/min, oxygen saturation 96% on air. Troponin is normal and echocardiogram shows normal right ventricular function. What is the most appropriate initial anticoagulation strategy?
Q27
A 70-year-old man presents with a 5-day history of productive cough with green sputum, fever, and left-sided pleuritic chest pain. He has type 2 diabetes and atrial fibrillation. On examination, temperature is 38.5°C, respiratory rate 24/min, heart rate 95/min (irregularly irregular), blood pressure 130/80 mmHg, oxygen saturation 93% on air. Chest examination reveals dullness to percussion and bronchial breathing at the left base. Blood tests show: WCC 16.5 × 10⁹/L, CRP 185 mg/L, urea 8.2 mmol/L. What is his CURB-65 score?
Q28
A 22-year-old woman with known asthma presents to the Emergency Department with acute breathlessness. She is speaking in single words, has a respiratory rate of 30/min, heart rate 125/min, and oxygen saturation 90% on air. Peak expiratory flow is 35% of her predicted value. She is unable to complete spirometry. Chest examination reveals widespread wheeze with reduced air entry bilaterally. What is the most appropriate immediate management?
Q29
A 65-year-old woman with COPD (FEV1 52% predicted, FEV1/FVC 0.65) presents with increasing breathlessness over the past year. She has had three exacerbations requiring oral antibiotics and corticosteroids in the last 12 months. She is a current smoker with a 40 pack-year history. Her current medication includes tiotropium once daily and salbutamol as needed. What is the most appropriate addition to her treatment regimen?
Q30
A 38-year-old man with asthma presents for review. He uses a beclometasone 200 micrograms twice daily inhaler and salbutamol as needed. He reports waking once per week due to asthma symptoms and uses his salbutamol inhaler 3-4 times per week. Peak flow is 85% of predicted. What is the most appropriate next step in his management according to BTS/SIGN guidelines?
Respiratory Medicine UK Medical PG Practice Questions and MCQs
Question 21: A 72-year-old man with COPD presents with his fourth exacerbation in the past 12 months. He is currently on triple therapy with tiotropium, salmeterol/fluticasone combination inhaler, and uses salbutamol as needed. He is an ex-smoker who stopped 5 years ago. Sputum cultures during previous exacerbations have grown Haemophilus influenzae on three occasions. His FEV1 is 38% predicted. He continues to have a productive cough with purulent sputum between exacerbations. What additional long-term treatment should be considered?
A. Long-term oxygen therapy assessment
B. Prophylactic azithromycin three times per week (Correct Answer)
C. Continuous oral prednisolone 5mg daily
D. Prophylactic co-trimoxazole daily
E. Roflumilast 500 micrograms daily
Explanation: ***Prophylactic azithromycin three times per week***
- This patient, with **severe COPD** (FEV1 38%), **frequent exacerbations** (4 in 12 months), a **chronic bronchitis phenotype** (productive cough with purulent sputum), and recurrent **Haemophilus influenzae** infections, meets criteria for macrolide prophylaxis.
- **Azithromycin** reduces exacerbation frequency through both its **antibacterial** and **anti-inflammatory** effects, making it an appropriate addition after optimizing triple therapy; however, clinicians must rule out **non-tuberculous mycobacteria** and check for **QT prolongation** prior to initiation.
*Long-term oxygen therapy assessment*
- **Long-term oxygen therapy (LTOT)** is indicated for patients with **chronic hypoxemia**, specifically if **PaO2** is consistently < 7.3 kPa or < 8.0 kPa with associated complications like **pulmonary hypertension**.
- The clinical vignette does not provide any **arterial blood gas** results or evidence of chronic hypoxemia that would warrant an immediate assessment for LTOT.
*Continuous oral prednisolone 5mg daily*
- **Long-term systemic corticosteroids** are generally avoided in COPD management due to severe and cumulative side effects such as **osteoporosis**, **myopathy**, **diabetes**, and **adrenal suppression**.
- While short courses may be used during exacerbations, continuous low-dose oral prednisolone is not a recommended strategy for routine exacerbation prevention in COPD.
*Prophylactic co-trimoxazole daily*
- **Co-trimoxazole** is not an evidence-based first-line agent for the prevention of COPD exacerbations in patients with recurrent bacterial infections.
- Its primary prophylactic role is typically in preventing **Pneumocystis jirovecii pneumonia** in immunocompromised individuals.
*Roflumilast 500 micrograms daily*
- **Roflumilast**, a phosphodiesterase-4 inhibitor, is considered for patients with severe COPD (FEV1 < 50%), a **chronic bronchitis phenotype**, and frequent exacerbations.
- While a valid consideration, the strong history of recurrent **Haemophilus influenzae** and persistent **purulent sputum** makes **prophylactic azithromycin** a more targeted and often preferred initial intervention to address the infectious component driving exacerbations.
Question 22: A 35-year-old woman who is 12 weeks pregnant presents with a 4-day history of cough productive of purulent sputum, fever, and left-sided chest pain. On examination, she is pyrexial at 38.2°C with a respiratory rate of 22/min and oxygen saturation of 94% on air. Chest examination reveals reduced breath sounds and dullness to percussion at the left lower zone. She has no past medical history and no known drug allergies. What is the most appropriate antibiotic choice?
A. Oral amoxicillin 500mg three times daily (Correct Answer)
B. Oral doxycycline 200mg loading dose then 100mg daily
C. Oral clarithromycin 500mg twice daily
D. Intravenous co-amoxiclav 1.2g three times daily
E. Oral levofloxacin 500mg once daily
Explanation: ***Oral amoxicillin 500mg three times daily***
- In a pregnant patient with **low-severity community-acquired pneumonia** (CURB-65 score of 0), oral **amoxicillin** is the first-line treatment choice.
- It is recognized as **safe in pregnancy** and provides excellent targeted coverage against **Streptococcus pneumoniae**, the most common causative organism.
*Oral doxycycline 200mg loading dose then 100mg daily*
- **Doxycycline** is strictly **contraindicated in pregnancy** as it can cross the placenta and interfere with **fetal bone development**.
- It is also associated with permanent **discoloration of the teeth** when administered during the second and third trimesters.
*Oral clarithromycin 500mg twice daily*
- This is an alternative for patients with a **penicillin allergy**, but it is generally avoided in the **first trimester** unless the benefit outweighs the risk.
- As this patient has no known allergies, **amoxicillin** remains the safer and more appropriate first-line empirical option.
*Intravenous co-amoxiclav 1.2g three times daily*
- **Intravenous antibiotics** are reserved for patients with high-severity scores or those unable to tolerate oral intake, which does not apply to this stable patient.
- **Co-amoxiclav** provides unnecessarily broad coverage for low-severity CAP and is not required for uncomplicated cases without specific risk factors.
*Oral levofloxacin 500mg once daily*
- **Fluoroquinolones** like levofloxacin are generally **contraindicated during pregnancy** due to concerns regarding **fetal cartilage toxicity**.
- They are typically reserved for severe, multi-drug resistant cases and are never first-line therapy for simple community-acquired pneumonia.
Question 23: A 44-year-old man attends the respiratory clinic for consideration of biologic therapy for his severe asthma. Despite maximal inhaled therapy (high-dose ICS/LABA plus LAMA) and maintenance oral prednisolone 10mg daily, he continues to have frequent exacerbations requiring hospital admission. Blood tests show: total IgE 850 IU/mL (normal <120), eosinophils 0.8 × 10⁹/L. Skin prick testing is positive to house dust mite and grass pollen. Which biologic agent would be the most appropriate first-line choice for this patient?
A. Omalizumab (Correct Answer)
B. Mepolizumab
C. Benralizumab
D. Dupilumab
E. Reslizumab
Explanation: ***Omalizumab*** - This patient meets the criteria for **severe allergic asthma**, defined by a high **total IgE (850 IU/mL)** and positive **skin prick testing** for perennial allergens. - Omalizumab is a monoclonal antibody that binds to **free IgE**, preventing it from binding to the **FcεRI receptor** on mast cells and basophils. *Mepolizumab* - This is an **anti-IL-5** monoclonal antibody primarily targeted at **eosinophilic asthma** phenotypes. - Although the patient has a blood eosinophil count of **0.8 × 10⁹/L**, the prominent allergic markers and IgE level make omalizumab the classic first-line choice in NICE/GINA guidelines for this specific phenotype. *Benralizumab* - Benralizumab targets the **IL-5 receptor alpha**, leading to direct depletion of **eosinophils** via antibody-dependent cell-mediated cytotoxicity. - It is highly effective for reducing exacerbations in **eosinophilic asthma**, but is typically reserved if the allergic criteria for omalizumab are not the primary driver. *Dupilumab* - This agent blocks the **IL-4 receptor alpha**, inhibiting both **IL-4 and IL-13** signaling pathways involved in Type 2 inflammation. - While it is effective for **oral corticosteroid-dependent asthma**, it is often considered an alternative or second-line choice compared to anti-IgE therapy in a clearly allergic patient. *Reslizumab* - Like mepolizumab, this is an **anti-IL-5** therapy, but it is unique because it is administered via **intravenous infusion** based on body weight. - It requires a minimum blood eosinophil count (often **≥0.4 × 10⁹/L**) and is indicated for severe eosinophilic asthma rather than primary allergic asthma.
Question 24: A 50-year-old woman is admitted with community-acquired pneumonia. She scores 2 on CURB-65 assessment. Blood cultures are taken and she is started on empirical antibiotic therapy. After 48 hours, she remains pyrexial with ongoing tachypnoea and hypoxia. Repeat chest radiograph shows progression of consolidation with a small pleural effusion. Blood cultures are negative. What is the most appropriate next step in her management?
A. Continue current antibiotics and reassess in 24 hours
B. Add clarithromycin to cover atypical organisms
C. Perform pleural aspiration for microscopy, culture and biochemistry (Correct Answer)
D. Change to intravenous co-amoxiclav and clarithromycin
E. Arrange CT chest to assess for complications
Explanation: ***Perform pleural aspiration for microscopy, culture and biochemistry***- In a patient with **pneumonia** who fails to respond to treatment and develops a **pleural effusion**, it is essential to sample the fluid to rule out a **complicated parapneumonic effusion** or **empyema**.- Pleural fluid analysis (pH, glucose, LDH, and microscopy/culture) is the gold standard for determining if a **chest drain** is required to achieve clinical resolution.*Continue current antibiotics and reassess in 24 hours*- Continuing management without intervention is incorrect because the patient is showing signs of **clinical deterioration** (tachypnoea, hypoxia, and pyrexia) and **radiological progression**.- Delaying diagnostic aspiration in the presence of a new effusion increases the risk of undiagnosed **pleural infection** and subsequent lung entrapment.*Add clarithromycin to cover atypical organisms*- While atypical coverage is standard for moderate-to-severe **CAP (CURB-65 score ">="2)**, it does not address the likely mechanical source of treatment failure, which is the **parapneumonic effusion**.- Empirical changes to antibiotics should ideally follow fluid sampling, as the effusion may reveal a specific **causative organism** or the need for drainage.*Change to intravenous co-amoxiclav and clarithromycin*- Changing antibiotics is premature before investigating the **pleural effusion**, which acts as a potential **focus of infection** that antibiotics alone may not penetrate effectively.- Escalating therapy without gathering diagnostic fluid data may mask the underlying problem and ignore the need for **intercostal drainage**.*Arrange CT chest to assess for complications*- While **CT chest** is useful for assessing complex lung pathology, it is not the first-line investigation for a simple-appearing effusion on a **chest radiograph**.- **Pleural aspiration** is a more rapid, cost-effective, and definitive diagnostic step to determine if the fluid is **exudative** or **infected**.
Question 25: According to BTS/SIGN guidelines for asthma management, what is the recommended starting dose of inhaled corticosteroid (beclometasone dipropionate equivalent) for an adult newly diagnosed with asthma requiring regular preventer therapy?
A. 200 micrograms twice daily
B. 400 micrograms twice daily (Correct Answer)
C. 100 micrograms twice daily
D. 800 micrograms twice daily
E. 1000 micrograms twice daily
Explanation: ***400 micrograms twice daily***
- According to **BTS/SIGN guidelines**, the recommended starting dose of inhaled corticosteroid (beclometasone dipropionate equivalent) for an adult newly diagnosed with asthma requiring regular preventer therapy is **400 micrograms per day**.
- This total daily dose is typically administered as **200 micrograms twice daily** and is categorized as a **low-dose ICS** (Step 2 in the management pathway).
*200 micrograms twice daily*
- While 200 micrograms is the amount taken per inhalation, this option specifies only one half of the **total daily dose** recommended for initiating therapy.
- The guidelines specify the total daily dose for therapeutic efficacy, not just the single administration amount.
*100 micrograms twice daily*
- This dose equates to a total of **200 micrograms per day**, which is considered a **very low dose** of ICS for adults.
- It is generally not the standard starting dose for adults according to the **BTS/SIGN asthma guidelines**, which recommend 400 micrograms/day at Step 2.
*800 micrograms twice daily*
- This would result in a total daily dose of **1600 micrograms**, which is classified as a **high dose** of ICS.
- High doses are reserved for patients with severe, uncontrolled asthma at **Step 4** or higher, not for initial preventer therapy.
*1000 micrograms twice daily*
- This equates to a total daily dose of **2000 micrograms**, an exceptionally high dose of inhaled corticosteroids.
- Such doses are typically used only in cases of **severe, refractory asthma** under specialist guidance due to increased risk of **systemic side effects**.
Question 26: A 56-year-old woman undergoes a CT pulmonary angiogram for suspected pulmonary embolism following an episode of pleuritic chest pain and breathlessness. The scan confirms a segmental PE in the right lower lobe. She has no past medical history and takes no regular medications. Her observations are: heart rate 88/min, blood pressure 128/76 mmHg, respiratory rate 18/min, oxygen saturation 96% on air. Troponin is normal and echocardiogram shows normal right ventricular function. What is the most appropriate initial anticoagulation strategy?
A. Commence warfarin with low molecular weight heparin bridging for minimum 3 months
B. Commence a direct oral anticoagulant (DOAC) for minimum 3 months (Correct Answer)
C. Commence unfractionated heparin infusion followed by warfarin for 6 months
D. Commence low molecular weight heparin for 6 months
E. Commence aspirin 300mg daily for 3 months
Explanation: ***Commence a direct oral anticoagulant (DOAC) for minimum 3 months***- **DOACs** (such as apixaban or rivaroxaban) are now recommended as **first-line therapy** for the management of venous thromboembolism (VTE) in patients without contraindications like severe renal failure or pregnancy.- This patient is **hemodynamically stable** with no evidence of **right ventricular (RV) strain** or myocardial injury (normal troponin), making her suitable for outpatient or standard inpatient DOAC therapy for at least **3 months**.*Commence warfarin with low molecular weight heparin bridging for minimum 3 months*- **Warfarin** is no longer considered first-line for most patients due to the requirement for **LMWH bridging** and frequent **INR monitoring**.- It is generally reserved for patients where DOACs are contraindicated, such as those with **antiphospholipid syndrome** or mechanical heart valves.*Commence unfractionated heparin infusion followed by warfarin for 6 months*- **Unfractionated heparin (UFH)** infusions are primarily indicated for patients with **massive PE** (hemodynamic instability) or high risk of bleeding where rapid reversal is needed.- A **6-month duration** is not the standard minimum; guidelines recommend a review at **3 months** to determine if long-term anticoagulation is necessary.*Commence low molecular weight heparin for 6 months*- **LMWH monotherapy** was historically the standard for **cancer-associated thrombosis**, but even in those cases, DOACs are now often preferred.- Routine use of LMWH for 6 months in a patient with no comorbidities is inappropriate given the availability of oral options with **superior patient convenience**.*Commence aspirin 300mg daily for 3 months*- **Aspirin** is insufficient for the acute treatment of a confirmed **pulmonary embolism** as it does not provide adequate anticoagulation to prevent clot propagation or recurrence.- Use of antiplatelets instead of anticoagulants in the acute phase of PE is associated with a high risk of **treatment failure** and mortality.
Question 27: A 70-year-old man presents with a 5-day history of productive cough with green sputum, fever, and left-sided pleuritic chest pain. He has type 2 diabetes and atrial fibrillation. On examination, temperature is 38.5°C, respiratory rate 24/min, heart rate 95/min (irregularly irregular), blood pressure 130/80 mmHg, oxygen saturation 93% on air. Chest examination reveals dullness to percussion and bronchial breathing at the left base. Blood tests show: WCC 16.5 × 10⁹/L, CRP 185 mg/L, urea 8.2 mmol/L. What is his CURB-65 score?
A. 1
B. 2
C. 3 (Correct Answer)
D. 4
E. 5
Explanation: ***2***
- The patient scores 1 point for **Age ≥65** (he is 70 years old) and 1 point for **Urea >7 mmol/L** (his urea is 8.2 mmol/L).
- He does not receive points for **Confusion** (not mentioned), **Respiratory rate ≥30/min** (his is 24/min), or **Blood pressure** (systolic <90 or diastolic ≤60 mmHg).
*1*
- This score would be incorrect as it fails to account for both the patient's **advanced age (70)** and the **elevated urea (8.2 mmol/L)**.
- A score of 1 indicates low risk, whereas this patient has at least two major **risk factors** according to the CURB-65 criteria.
*3*
- A score of 3 would require an additional clinical marker such as **new-onset confusion**, a respiratory rate of **30/min or higher**, or hypotension.
- While the patient has high inflammatory markers (**CRP 185**), these are not part of the standardized **CURB-65 severity assessment**.
*4*
- This score implies severe pneumonia with four criteria met, but this patient's **hemodynamics** (BP 130/80) and **breathing rate** (24/min) are within the non-scoring range.
- Scoring a 4 requires significant physiological derangement not present in this clinical scenario.
*5*
- A score of 5 represents the maximum severity score, requiring the presence of **all five criteria** including hypotension and confusion.
- This patient is **hemodynamically stable** and does not meet the criteria for a high-dependency or intensive care admission based strictly on this score.
Question 28: A 22-year-old woman with known asthma presents to the Emergency Department with acute breathlessness. She is speaking in single words, has a respiratory rate of 30/min, heart rate 125/min, and oxygen saturation 90% on air. Peak expiratory flow is 35% of her predicted value. She is unable to complete spirometry. Chest examination reveals widespread wheeze with reduced air entry bilaterally. What is the most appropriate immediate management?
A. Nebulised salbutamol 5mg and ipratropium 500 micrograms, oxygen via face mask, oral prednisolone 40mg
B. Nebulised salbutamol 5mg, oxygen via nasal cannulae at 2L/min, arrange chest radiograph
C. Intravenous magnesium sulphate 2g, oxygen via non-rebreathe mask, call intensive care
D. Nebulised salbutamol 5mg and ipratropium 500 micrograms, oxygen via non-rebreathe mask, hydrocortisone 100mg IV (Correct Answer)
E. Nebulised adrenaline, oxygen via non-rebreathe mask, prepare for intubation
Explanation: ***Nebulised salbutamol 5mg and ipratropium 500 micrograms, oxygen via non-rebreathe mask, hydrocortisone 100mg IV***
- The patient's presentation with **SpO2 90%**, speaking in **single words**, and **PEFR 35% predicted** indicates a **life-threatening asthma** attack, requiring aggressive immediate management.
- This regimen provides crucial **high-flow oxygen**, dual **nebulised bronchodilators** (salbutamol and ipratropium), and prompt **intravenous corticosteroids** (hydrocortisone) suitable for a patient too breathless for oral intake.
*Nebulised salbutamol 5mg and ipratropium 500 micrograms, oxygen via face mask, oral prednisolone 40mg*
- While correct medications are included, **oral prednisolone** is less appropriate than IV hydrocortisone when the patient is speaking in **single words** and at high risk of deterioration or difficulty swallowing.
- A standard **face mask** may not deliver the necessary **high-concentration oxygen** required for initial stabilization in life-threatening asthma compared to a non-rebreathe mask.
*Nebulised salbutamol 5mg, oxygen via nasal cannulae at 2L/min, arrange chest radiograph*
- **Nasal cannulae at 2L/min** are inadequate for a patient with **hypoxia (90%)** and significant respiratory distress; high-concentration oxygen delivery is essential.
- This option crucially omits **ipratropium bromide** and **systemic corticosteroids**, both cornerstone therapies for severe and life-threatening asthma exacerbations.
*Intravenous magnesium sulphate 2g, oxygen via non-rebreathe mask, call intensive care*
- **IV magnesium sulphate** is typically a **second-line treatment** for severe asthma, used when there's an inadequate response to initial bronchodilator and corticosteroid therapy.
- This option misses the critical immediate administration of **nebulised bronchodilators** (salbutamol and ipratropium) and **systemic corticosteroids**, which are first-line.
*Nebulised adrenaline, oxygen via non-rebreathe mask, prepare for intubation*
- **Nebulised adrenaline** is indicated for **upper airway obstruction** or croup, not as a primary treatment for **bronchial asthma** exacerbations.
- While intubation may become necessary, initial efforts must focus on aggressive **pharmacological management** with bronchodilators and steroids to prevent respiratory failure before resorting to intubation.
Question 29: A 65-year-old woman with COPD (FEV1 52% predicted, FEV1/FVC 0.65) presents with increasing breathlessness over the past year. She has had three exacerbations requiring oral antibiotics and corticosteroids in the last 12 months. She is a current smoker with a 40 pack-year history. Her current medication includes tiotropium once daily and salbutamol as needed. What is the most appropriate addition to her treatment regimen?
A. Add a long-acting beta-2 agonist only
B. Add an inhaled corticosteroid only
C. Add a combination inhaled corticosteroid and long-acting beta-2 agonist (Correct Answer)
D. Add oral theophylline
E. Add prophylactic azithromycin
Explanation: ***Add a combination inhaled corticosteroid and long-acting beta-2 agonist***
- This patient, with **three exacerbations** in the last year while on a **LAMA (tiotropium)** and an FEV1 of 52%, falls into the **GOLD Group E** (high risk for exacerbations).
- Escalating to **triple therapy (LAMA + LABA + ICS)** is the recommended strategy for such patients to significantly reduce the frequency of moderate-to-severe exacerbations and improve lung function.
*Add a long-acting beta-2 agonist only*
- While adding a **LABA** to a **LAMA** (dual bronchodilation) is a step up and can improve breathlessness, it may not be sufficient for a patient with such frequent exacerbations (three in a year).
- The absence of an **inhaled corticosteroid (ICS)** in this scenario means the inflammatory component of her severe COPD and exacerbation risk is not adequately addressed.
*Add an inhaled corticosteroid only*
- **Inhaled corticosteroid (ICS) monotherapy** is explicitly not recommended for COPD due to an increased risk of **pneumonia** and a lack of proven efficacy in reducing exacerbations without a bronchodilator.
- ICS should always be combined with at least one long-acting bronchodilator (**LABA**) in COPD management when indicated.
*Add oral theophylline*
- **Theophylline** has a narrow **therapeutic index**, requiring careful monitoring of blood levels, and carries a higher risk of adverse effects compared to inhaled therapies.
- It is generally considered a second-line agent or an add-on therapy, typically used after optimizing inhaled bronchodilator and corticosteroid regimens.
*Add prophylactic azithromycin*
- **Prophylactic macrolides** like azithromycin are typically reserved for patients who continue to experience frequent exacerbations despite optimal **triple inhaled therapy** and adherence to other non-pharmacological interventions like smoking cessation.
- Initiating this therapy before optimizing inhaled regimens is premature and may lead to antibiotic resistance without addressing primary airway management.
Question 30: A 38-year-old man with asthma presents for review. He uses a beclometasone 200 micrograms twice daily inhaler and salbutamol as needed. He reports waking once per week due to asthma symptoms and uses his salbutamol inhaler 3-4 times per week. Peak flow is 85% of predicted. What is the most appropriate next step in his management according to BTS/SIGN guidelines?
A. Add a leukotriene receptor antagonist
B. Add a long-acting beta-2 agonist (Correct Answer)
C. Increase beclometasone to 400 micrograms twice daily
D. Add theophylline
E. Add oral prednisolone
Explanation: ***Add a long-acting beta-2 agonist***
- According to **BTS/SIGN guidelines**, for patients uncontrolled on low-dose **inhaled corticosteroids (ICS)**, the preferred **Step 3** intervention is the addition of a **long-acting beta-2 agonist (LABA)**.
- This patient demonstrates poor control with **nocturnal symptoms** and frequent **SABA** use, making the addition of a LABA the most appropriate next step for improved symptom control.
*Add a leukotriene receptor antagonist*
- A **leukotriene receptor antagonist (LTRA)** is typically considered at **Step 3** as an alternative to a LABA, or if there is an inadequate response to a LABA, or if LABAs are not tolerated.
- While it is a valid add-on therapy, the **first-line** recommendation for initial escalation from low-dose ICS in this scenario is generally a LABA.
*Increase beclometasone to 400 micrograms twice daily*
- Increasing the **ICS dose** to medium-dose is generally reserved for when a patient has an inadequate response to the combination of **low-dose ICS and LABA** (i.e., Step 4).
- Guidelines prioritize adding a **LABA** first at Step 3 as it often provides superior symptom control and reduces the need for higher doses of ICS, thus minimizing potential **ICS-related side effects**.
*Add theophylline*
- **Theophylline** is a fourth-line or specialized agent used when asthma remains poorly controlled despite **ICS**, **LABA**, and often **LTRA** therapy.
- It requires **therapeutic drug monitoring** due to a narrow therapeutic window and has a significant side-effect profile, making it inappropriate at this relatively early stage of management.
*Add oral prednisolone*
- **Oral prednisolone** is typically reserved for **Step 5** management of chronic severe asthma or for the management of **acute exacerbations**.
- Using oral steroids at this stage would be premature, as the patient has not yet exhausted standard **inhaled maintenance therapies** such as a LABA add-on.
